# data[].attributes.headline
Una revisión narrativa del manejo farmacéutico de la osteoporosis.

# data[].attributes.subject
Una revisión narrativa del manejo farmacéutico de la osteoporosis.

# data[].attributes.body
Patel, D., Gorrell, C., Norris, J., & Liu, J. (2023). A narrative review of the pharmaceutical management of osteoporosis. Annals of joint, 8, 25. https://doi.org/10.21037/aoj-23-2

# data[].attributes.attachment_link.readable_text
Abstract

Background and Objective

Osteoporosis is a skeletal disorder classified by the loss of bone density in older adults leading to compromised bone strength and an increased risk of fracture. It can be divided into categories based on its etiology: senile, post-menopausal, and secondary osteoporosis. Specific prevention measures and treatments exist for targeting bone loss. Here we review and summarize the literature regarding the presentation of osteoporosis and discuss pharmaceutical therapies.

Methods

PubMed and Google Scholar were searched for articles published in English between 1980 and 2021. Search terms combined "senile osteoporosis", "osteoporosis treatment", "osteoporosis", "bisphosphonates", "denosumab", types of hormone therapy, and other relevant keywords used in various combinations.

Key Content and Findings

Osteoporosis affects millions but often goes undiagnosed until a pathologic fracture. Dual-energy X-ray absorptiometry (DEXA) scans evaluate bone mineral density (BMD) and are a diagnostic tool for osteoporosis. Adults over the age of 65, post-menopausal women, and those with risk factors such as previous fractures are recommended to receive DEXA scans every one to two years. Bisphosphonates, denosumab, and hormonal therapies are among the most common pharmacologic treatments for osteoporosis.

Conclusions

Daily, orally administered bisphosphonates are the first-line therapy for osteoporosis given their efficacy in decreasing fracture risk and favorable safety profile. Denosumab is an alternative that is administered subcutaneously every six months and may be given as initial therapy to select patients. Hormonal therapies are used if patients cannot tolerate bisphosphonates or denosumab or are refractory to these medications. Preventative measures for osteoporosis include tailored exercise and sufficient intake of calcium and vitamin D via diet or supplementation.

Keywords: Osteoporosis, pharmacology, bisphosphonates, denosumab

Introduction

Background

A 2014 study reported a 10.3% prevalence of osteoporosis among Americans 50 years or older, equating to 10.2 million people, with an additional 43.4 million experiencing low bone mass ( 1). Additionally, the annual healthcare cost of osteoporosis and related fractures was estimated to be $16 billion in 2008 ( 2). These costs are predicted to increase to $25.3 billion by 2025, with approximately 3 million fractures caused by the disorder ( 3). Deformities including kyphosis and related height loss often accompany senile osteoporosis ( 4). These financial and physical burdens are likely to grow along with the aging population in the coming years.

Rationale and knowledge gap

Current treatments for osteoporosis include lifestyle modification, pharmacological management, minimally invasive procedures, and extensive surgical treatments. However, only pharmacological management is recognized as treatment for the cause. There is limited literature that provides the efficacy of various medications for osteoporosis and other relevant pharmacological data in a single compiled manuscript.

Objective

The aim of this review is to focus on the pharmacological management of osteoporosis to provide a succinct source of data for practitioners. This review begins with an overview of osteoporosis and its diagnosis, then we discuss the specific medications that can be used to treat osteoporosis, starting with the first-line treatment of bisphosphonates and denosumab and then hormonal therapy. The efficacy of the various medications will also be discussed, along with comparisons between first- and second-line treatments. Finally, we present lifestyle modifications and nutrient supplementations that can influence the pathogenesis of osteoporosis. We present this article in accordance with the Narrative Review reporting checklist (available at https://aoj.amegroups.org/article/view/10.21037/aoj-23-2/rc).

Methods

A comprehensive search of PubMed and Google Scholar was conducted for articles published between 1980 and 2021 in English (Table 1 and Table S1). Search terms included "osteoporosis", "senile osteoporosis", "osteoporosis pharmacology", and "treatment". Other relevant keywords were included in various combinations for searches. Articles were also collected by critically examining the reference lists of publications found in the database search. Exclusion criteria included cadaveric studies.

Table 1

Items

Specification

Date of search

March 30, 2022

Databases and other sources searched

PubMed, Google Scholar

Search terms used

Osteoporosis, Osteoporosis treatment, Senile osteoporosis, Osteoporosis pharmacology, Osteoporosis medication, Bisphosphonate, Alendronate, Ibandronate, Risedronate, Zoledronate, Denosumab, Raloxifene, Teriparatide, Abaloparatide, Calcitonin

Timeframe

1980-2021

Inclusion and exclusion criteria

Inclusion criteria: (I) written in English; (II) reporting various outcome measurements of different medications; (III) peer-reviewed

Exclusion criteria: (I) articles not written in English; (II) studies only reporting drug-induced osteoporosis; (III) posters or abstracts at annual meetings; (IV) graduate theses without peer-reviewed publication of an article

Selection process

Three authors independently reviewed the title and abstracts of each article identified in the search. If the articles were appropriate and additional information was necessary, full-text articles were retrieved and data were extracted. If three authors differed on whether to include an article, the fourth author was consulted to achieve consensus

Discussion

Pathophysiology

Osteoporosis may be of a primary or secondary origin, with primary osteoporosis arising more frequently in post-menopausal women but affecting both sexes in old age as bone density and estrogen levels naturally decline ( 5). Secondary osteoporosis results when the decreased bone density is due to another conduction, such as hypogonadism or celiac disease, or medications, such as glucocorticoids ( 6).

Osteoporosis reduces bone volume and integrity, rendering patients vulnerable to fracture and deformity. This can be attributed to an imbalance of osteoblast and osteoclast activity, which results in unequal bone formation and bone reabsorption, respectively ( 7). Estrogen deficiency may also lead to osteoporosis as estrogen plays an important role in increasing the storage pool of pre-osteoclasts, as well as upregulating transforming growth factor beta (TGF-β), a cytokine that decreases osteoclast activity. Calcium and vitamin D deficiencies also increase the risk of developing osteoporosis because when less calcium is absorbed from the intestinal tract, there is an increased release of stored calcium via osteoclasts in bones to increase serum calcium. The increased osteoclastic activity causes further bone loss and an increased risk of fractures ( 5).

It is estimated that 1 in 2 women along with up to 1 in 4 men 50 years old and older living with osteoporosis will break a bone due to the disorder. Since osteoporosis weakens bone strength, bone fractures are typically the first sign of the disorder, as one is not able to feel their bones weakening. These fractures are mostly seen in the hip, distal radius, and spine. While these are the frequently seen fractures, there has been an increase in the number of fractures and the types of fractures that should be considered osteoporotic ( 4). Those who experience a fracture are at an increased risk of subsequent fractures in the future: 10% within one year, 18% within two years, and 31% within 5 years ( 8). Kyphosis is another sign seen in those with osteoporosis, which can lead to visible height loss ( 4).

Diagnosis

Fractures are typically the first indicator of osteoporosis, as age-related loss of bone density is otherwise difficult to perceive. Estimates of bone mineral density (BMD) can be made using noninvasive dual-energy X-ray absorptiometry (DEXA). The National Osteoporosis Foundation (NOF) recommends BMD testing via DEXA based on age, sex, and risk factors ( 9) (Table 2 ). After diagnosis and initiation of therapy, BMD testing should be repeated every two years, and more often in the case of recurring fractures ( 10). The time between scans can also be increased to 15 years in patients with normal BMD or mild osteopenia or five years in patients with moderate osteopenia ( 11). Osteopenia can be distinguished from osteoporosis by the T-score of BMD testing, with a T-score between −1.01 and −2.49 indicating osteopenia and −2.50 or lower being osteoporosis ( 11). While it is important to note that BMD test results do not always correlate with fracture probability, early identification of low BMD can inform preventative clinical decision-making ( 12).

Table 2

Women

Men

Age 65 and older

Age 70 and older

Age below 65 and post-menopausal

Age 50-69 with risk factors

Age 50 and older with history of fracture in adulthood

Pharmacological management

First line-bisphosphonates

Mechanism of action and efficacy

Bisphosphonates are Food and Drug Administration (FDA)-approved for the prevention and treatment of osteoporosis. Due to their high affinity for bone mineral and ability to bind to hydroxyapatite crystals, these drugs work well to inhibit osteoclast activation and decrease bone resorption, thereby decreasing bone loss ( 13- 15). The mechanism of action for bisphosphonates varies by generation due to the difference in structure. First-generation non-nitrogen-containing bisphosphonates are incorporated into nonhydrolyzable adenosine triphosphate (ATP) once taken up by osteoclasts on the bone surface. These nonhydrolyzable ATP accumulate, inhibiting numerous ATP-dependent cellular processes, which leads to osteoclast apoptosis. Examples of first-generation bisphosphonates include etidronate, clodronate, and tiludronate. Second- and third-generation bisphosphonates, also called aminobisphosphonates, contain a nitrogen side chain, which allows the drug to inhibit the continuation of the mevalonic acid pathway by binding to and inactivating farnesyl pyrophosphate synthase. This disruption further causes inhibition of posttranslational modifications of proteins, causing osteoclast apoptosis. Alendronate, risedronate, ibandronate, pamidronate, and zoledronic acid are a few of the second- and third-generation bisphosphonates. Another differentiation between the classes of drugs is what cells they target. Non-nitrogen-containing bisphosphonates can affect mammalian cells expressing farnesyl pyrophosphate synthase, whereas nitrogen-containing-bisphosphonates only cause apoptosis in osteoclasts due to their selective affinity to bone mineral ( 15). This differentiation could be a contributing factor to why nitrogen-containing bisphosphonates are the favorable choice for the treatment of osteoporosis.

Bisphosphonates can be administered orally after a prolonged fast with water and nothing by mouth for 30-60 minutes after or given intravenously ( 16). The most common side effects are gastrointestinal, including reflux and esophagitis ( 17). Some rare adverse complications of bisphosphonates include osteonecrosis of the jaw and atypical fractures ( 16). The use of bisphosphonates and osteonecrosis of the jaw appear to be more prevalent in patients with cancer, but a causal linkage has not been established due to the small number of cases. Similarly, more conclusive data are needed to associate atypical fractures and bisphosphonates as some reports make it difficult to distinguish if the cause of these fractures is due to the medication use or osteoporosis. Despite having a short plasma half-life, bisphosphonates can remain in bone for years ( 16, 18).

Alendronate, an aminobisphosphonate, is one of the most popular prescribed medications for osteoporosis treatment, with approximately 2.01 million US patients estimated to be taking the drug in 2020, according to the Medical Expenditure Panel Survey (MEPS) administered by the Agency for Healthcare Research and Quality (AHRQ) ( 19). Specifically, for postmenopausal osteoporosis, alendronate has been the most popular anti-osteoporosis drug since 1996 ( 20). Alendronate decreases the risk of vertebral, non-vertebral, and hip fractures in postmenopausal women when compared to calcium and vitamin D supplementation ( 21). Over two years, daily administration of alendronate, 10 mg, increased BMD in the lumbar spine and total hip by 7.4% and 4.3%, respectively (Table 3 ). This was a slightly higher increase when compared to a once-weekly administration of alendronate, 70 mg, with lumbar spine and total hip results of 6.8% and 4.1%, respectively. Because these two administration frequencies are therapeutically equivalent, it is suggested to prescribe the once-weekly regimen as it is more convenient and can enhance compliance ( 40, 41).

In terms of fracture risk for postmenopausal women, daily alendronate for one year provided a 47% risk reduction in nonvertebral fractures relative to a placebo ( 42). Daily alendronate can be tolerable for an extended period, with some treatments lasting up to 10 years. During a 10-year treatment of 10 mg daily alendronate, an increase in BMD was seen, with the greatest in the lumbar spine (13.7%), followed by the trochanter (10.3%), total proximal femur (6.7%), and femoral neck (5.4%) ( 22).

In men with osteoporosis, alendronate significantly increases the BMD of the spine, hip, and total body, along with decreasing the incidence of vertebral fractures over nonvertebral fractures ( 23, 24).

Another aminobisphosphonate that can be used in osteoporosis treatment is ibandronate. Ibandronate can significantly increase BMD after 12 months of treatment. Administration of ibandronate in postmenopausal women after a cementless total hip arthroplasty can decrease the amount of bone loss within six months ( 43). Of note, ibandronate has been shown to only prevent spinal fractures and not hip or non-vertebral fractures, despite increasing BMD ( 21, 44).

Risedronate is a third-generation aminobisphosphonate that is suggested to be one of the first bisphosphonates prescribed when treating osteoporosis. Over three years, risedronate has been shown to reduce the rate of vertebral fractures by 41% and nonvertebral fractures by 39% ( 25). In terms of BMD, when compared to placebo, risedronate had a greater effect on increasing the BMD of the lumbar spine, femoral neck, femoral trochanter, and midshaft of the radius ( 25). For women with osteoporosis, between the ages of 70-79, the incidence of hip fractures when treated with risedronate is notably lower than the placebo group, 1.9% and 3.2% respectively ( 45). Risedronate is more potent than alendronate, but overall leads to less of an increase in BMD; however, it remains a viable treatment, especially when considering patients who cannot tolerate the gastrointestinal side effects of alendronate ( 21, 46, 47).

Zoledronate is an intravenous aminobisphosphonate that can be administered once yearly and has the highest potency in its class. In postmenopausal women, it considerably decreased the risk of morphometric vertebral fracture by 70% and hip fractures by 41%. Zoledronate was also shown to decrease the risk of nonvertebral and clinical vertebral fractures by 25% and 77%, respectively. Additionally, it markedly increased the BMD of the total hip (6.02%), lumbar spine (6.71%), and femoral neck (5.06%) ( 26). When comparing three and six years of zoledronate infusions, there were no significant differences in the incidence of clinical fractures; meanwhile, there were increases, albeit non-significant, in serious atrial fibrillation events and stroke in the group receiving six years of treatment, showing zoledronate is preferred in a three-year regimen ( 48). Interestingly, a single infusion has been shown to have a similar reduction in fracture rate compared to three infusions, 32% and 34%, respectively ( 49). Further studies are needed to directly compare the efficacy of zoledronate and oral bisphosphonates.

Depending on the patient's risk of fractures, a bisphosphonate drug holiday could be warranted. Because bisphosphonates accumulate in bone and continue to have effects after discontinuation of treatment, it is not necessary for low-risk patients to continue the regimen. For these patients, treatment can be stopped after approximately five years and does not need to continue if bone density is stable and there are no fractures. For higher-risk patients, bisphosphonate therapy can be initiated for 10 years followed by a holiday of one or two years, maximum. Non-bisphosphonate therapy could be indicated for higher-risk patients during their drug holiday ( 16). The length of the drug holiday depends on the specific bisphosphonate. For example, discontinuation from risedronate would have a shorter drug holiday (1-2 years) compared to zoledronate (3-6 years) ( 50). During the drug holiday, the patient's bone density and relevant markers should be monitored ( 16). For all patients, if there is a fracture or other factors arise that increase fracture risk, then bisphosphonate or other osteoporosis therapy should be initiated.

Second line-denosumab and hormonal therapy

Denosumab: mechanism of action and efficacy

Denosumab is a human monoclonal antibody that decreases bone resorption by inhibiting receptor activator of nuclear factor kappa-Β ligand (RANKL), which is involved in the formation and activation of osteoclasts. It is administered every six months subcutaneously by a healthcare professional, benefiting those patients who cannot use oral therapy or are at high risk for fractures ( 27, 51, 52). Fatigue and weakness are some adverse effects associated with denosumab ( 53). It has been shown to decrease hip, vertebral, and non-vertebral fractures when compared to calcium and vitamin D supplementation ( 52). In postmenopausal women, denosumab reduced the risk of radiographic vertebral fractures by 68%, hip fractures by 40%, and non-vertebral fractures by 20% ( 28). After discontinuation of denosumab, or other anabolic treatments, patients should transition to oral bisphosphonates to prevent bone loss ( 51).

Hormonal therapy: mechanism of action and efficacy

Hormonal therapy can also be implemented for the prevention and treatment of postmenopausal osteoporosis. However, the use of hormone replacement therapy has declined due to increasing the risk of cardiovascular complications, including stroke and coronary heart disease, and breast cancer ( 21, 52, 54, 55). One class of hormone therapy is selective estrogen receptor modulators (SERMs), such as raloxifene. Depending on the target tissue, SERMs act as estrogen receptor agonists or antagonists ( 56). Raloxifene is the only drug of its class to be approved for the prevention and treatment of osteoporosis ( 16). It is administered daily by mouth and decreases the risk of vertebral fractures only ( 29, 30). Before prescribing, the benefits of raloxifene should be weighed against the potential adverse effects, such as venous thromboembolism. Combination therapy, such as estrogen-plus-progestin, has been shown to reduce the risk of hip, vertebral, and wrist fractures ( 54). Even so, the risks of cardiovascular disease and breast cancer do not outweigh the benefits, so it is recommended that these therapies be limited in their usage and not used for long-term treatment ( 54, 57).

Another class of hormones that has been evaluated for the prevention and treatment of osteoporosis is parathyroid hormone analogs, such as teriparatide and abaloparatide. Teriparatide is an anabolic agent that has been shown to increase bone mass by stimulating osteoblasts ( 31, 58). It increases vertebral and hip BMD more than alendronate ( 32, 33, 59). Abaloparatide has also been implicated in better reducing the risk of vertebral fracture than alendronate, but additional studies are needed to strengthen this finding ( 60).

Calcitonin, a thyroid hormone, is indicated for the treatment of osteoporosis in women who have been postmenopausal for at least five years ( 16). Calcitonin inhibits bone resorption by disrupting the ruffled border of osteoclasts, which causes the cells to move away from bone and thus decreases resorption ( 61). These morphological changes are observed as soon as 15 minutes after treatment and reach maximal effect within 1 hour ( 61). Calcitonin is primarily administered intranasally, whereas in the past it was parenterally administered. The efficacy of calcitonin has been variable due to several limitations in multiple studies. However, a meta-analysis by Cranney et al. [2002] suggested that calcitonin can increase bone density in postmenopausal women and potentially decrease the risk of vertebral fracture ( 62). Future studies need to address the potential publication bias surrounding calcitonin's efficacy in treating osteoporosis. An interesting clinical application of calcitonin would be its use as an analgesic to relieve osteoporotic bone pain, but more studies are needed to understand this mechanism since it is independent of calcitonin's metabolic effect ( 63).

Comparison of first and second line

Even though bisphosphonates are typically the first-line treatment for osteoporosis, denosumab and other effective medications contribute to the controversy around osteoporosis treatment. Multiple meta-analyses have demonstrated denosumab increases BMD of the distal radius, femoral neck, lumbar spine, and total hip, more so than bisphosphonates, but does not decrease the fracture risk relative to bisphosphonates ( 64- 66). Therefore, denosumab and bisphosphonates may be indicated for two different populations: denosumab for patients at low-risk for fracture with low BMD and bisphosphonates for patients at high-risk for fracture regardless of BMD. Additionally, denosumab and other non-oral medications are indicated for patients who cannot take oral medications or who have not responded to bisphosphonates ( 52). The American College of Physicians (ACP) strongly recommends treatment with alendronate, risedronate, zoledronate, or denosumab for women with known osteoporosis to reduce the risk for hip and vertebral fractures ( 67). However, there are fewer studies involving men with osteoporosis, so the ACP weakly recommends bisphosphonates to decrease the risk of vertebral fractures in men with clinically recognized osteoporosis ( 67). It is also important for practitioners to consider patients' access to healthcare and the feasibility of a medication regimen. For example, elderly patients, who are typically affected by osteoporosis, may have difficulty traveling to receive treatment that needs to be administered by a healthcare professional, such as zoledronate or denosumab. In these instances, an oral pill that could be taken at home would be preferable. However, a medication only administered once a year could be preferred over a pill that needs to be taken daily. Because of the various treatment methods, it is important to discuss the different regimens with the patients to ensure compliance with the regimen.

Lifestyle and supplement prevention methods

Osteoporosis may be prevented by altering modifiable risk factors such as inadequate exercise and nutrition ( 68). Walking and low-impact aerobic exercise can prevent a decrease in BMD, while high-impact aerobic exercise and weight training can increase BMD in the hips and lumbar spine ( 69). As BMD naturally declines with age, effective prevention can begin early to ensure healthy development before BMD peaks in the third and fourth decades of life ( 70). High-impact exercise such as jumping leads to increased bone mass in children that can be maintained for several years ( 71). However, these benefits are diminished in post-menopausal women, emphasizing the importance of early prevention ( 72). In cases of senile osteoporosis, exercise regimens must also be designed to diminish the potential for falls and fractures. Although there is no standardized exercise regimen for elderly patients, most focus on improving muscle strength and balance through resistance training, weight-bearing impact exercise, and functionally challenging mobility activities ( 68, 73).

Certain nutrients, such as vitamin D and calcium, are essential for bone strength. However, there have been multiple observations of low vitamin D and calcium intake in the elderly ( 68, 74). The NOF recommends postmenopausal women and men over 65 years old should consume at least 1,200 mg of elemental calcium daily; anyone over the age of 50 should consume at least 800-1,000 IU of vitamin D daily ( 75, 76). Vitamin D-fortified foods have also been shown to significantly increase BMD, but adequate intake is uncommon in geographical areas with lesser annual sun exposure, suggesting many could benefit from supplementation ( 77, 78). A meta-analysis conducted by the NOF found a 30% reduction in the risk of hip fractures and a 15% reduction in the risk of total fractures in adults with calcium plus vitamin D supplementation ( 79). While dietary modifications or supplementation can be highly beneficial to older adults at risk for osteoporosis, longitudinal optimization of intake beginning as early as childhood is ideal.

Strengths and limitations

This review summarizes the current literature on the pharmacology of osteoporosis and relevant clinical information, including physiology and effectiveness. By compiling this information in a single review, clinicians will have quicker access to relevant information and the original sources for further investigation. Despite these strengths, there are some limitations to this narrative review. There were only two databases searched and they were not exhaustively explored; the search was limited to the most relevant articles using select keywords. The quality of the studies referenced was not assessed using a standardized methodology, although the authors preferentially chose meta-analyses and systematic reviews. Another limitation is the relative lack of literature in certain osteoporotic populations, such as men or drug-induced; much of the studies focus on post-menopausal women. Future studies should address these other populations and include them in comparison studies between different classes of medications for osteoporosis.

Conclusions

Osteoporosis is a highly prevalent condition that is growing along with aging and expanding populations. It carries a large financial burden, and its related fractures can significantly decrease quality of life. Despite the availability of DEXA, many cases of osteoporosis are not diagnosed until a fracture occurs. These often include vertebral compression fractures, hip fractures, and distal radius fractures, which can cause significant pain and functional impairment. First-line treatment for osteoporosis includes bisphosphonates, which can increase lumbar spine BMD between 5.4% (risedronate over three years) and 13.7% (alendronate over 10 years) and femur BMD between 1.6% (femoral neck, risedronate over three years) and 13.7% (femoral trochanter, alendronate over 10 years). Bisphosphonates also decrease the incidence/risk of fracture, ranging from a 25% decrease (nonvertebral fracture, zoledronate over three years) to a 77% decrease (vertebral fracture, zoledronate over three years). Denosumab is a RANKL inhibitor that can decrease the risk of radiographic vertebral fractures by 68% when used over three years. Hormone therapy can also be used to manage osteoporosis if the first-line treatments are not possible or patients are refractory to them. Raloxifene, a SERM, can increase lumbar spine and femoral neck BMD by approximately 2.6% and 2.3%, depending on the dosage. Teriparatide, a parathyroid hormone analog, can increase lumbar spine BMD between 7.2% and 17.8%, depending on time and dosage. Prevention measures include BMD-promoting exercise and dietary adjustment in earlier life, which may also slow BMD decline in older adults. Educating young patients about osteoporosis may prompt them to adopt lifestyle changes that can prevent exacerbation of the condition in old age. Adoption of BMD screening can help identify early cases of osteoporosis that could benefit from medical intervention. Future development of medical devices, surgical techniques, and medications could minimize complications and burdens of living with osteoporosis. Similarly, additional research may identify previously unrecognized preventative measures.

Supplementary

The article's supplementary files as

Notes

Ethical Statement: The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

References

3. Dempster DW. Osteoporosis and the burden of osteoporosis-related fractures. Am J Manag Care 2011;17 Suppl 6:S164-9. [[ PubMed] Google Scholar]

21. Ralston S. Bisphosphonates for Osteoporosis. In: Harrison-Woolrych M. editor. Medicines For Women. Cham: Springer International Publishing; 2015:345-71. [ Google Scholar]

34. Hildebrand GK, Kasi A. Denosumab. StatPearls. Treasure Island (FL); 2022. [ Google Scholar]

36. McLaughlin MB, Jialal I. Calcitonin. StatPearls. Treasure Island (FL); 2022. [ Google Scholar]

41. Schnitzer T, Bone HG, Crepaldi G, et al. Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis. Alendronate Once-Weekly Study Group. Aging (Milano) 2000;12:1-12. [[ PubMed] Google Scholar]

43. Muratore M, Quarta E, Quarta L, et al. Ibandronate and cementless total hip arthroplasty: densitometric measurement of periprosthetic bone mass and new therapeutic approach to the prevention of aseptic loosening. Clin Cases Miner Bone Metab 2012;9:50-5. [[ PubMed] PMC free article] [ Google Scholar]

52. Jeremiah MP, Unwin BK, Greenawald MH, et al. Diagnosis and Management of Osteoporosis. Am Fam Physician 2015;92:261-8. [[ PubMed] Google Scholar]

Articles from Annals of Joint are provided here courtesy of AME Publications

# data[].attributes.attachment_link.title
A narrative review of the pharmaceutical management of osteoporosis

# data[].attributes.attachment_link.description
Osteoporosis is a skeletal disorder classified by the loss of bone density in older adults leading to compromised bone strength and an increased risk of fracture. It can be divided into categories based on its etiology: senile, post-menopausal, and secondary ...

# data[].attributes.headline
Initial Treatment Trends in Patient With Osteoporosis

# data[].attributes.subject
Initial Treatment Trends in Patient With Osteoporosis

# data[].attributes.body
Carbonell, C., Díez, A., Calaf, J., Caloto, M. T., Nocea, G., & Lara, N. (2012). Pauta de tratamiento inicial en pacientes con osteoporosis: uso de antirresortivos y suplementos farmacológicos (calcio y vitamina D) en la práctica clínica. Reumatología Clínica, 8(1), 3-9.

# data[].attributes.wish_content.attachment_props.alternative_text
Initial Treatment Trends in Patient With Osteoporosis

# data[].attributes.attachment_link.readable_text
The .gov means it's official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Abstract

Objective: To describe the percentage of prescription of pharmacologic supplements in patients starting antiresorptive treatment (ART) for osteoporosis by specialists.

Design: Cross-sectional, naturalistic, multicenter study with retrospective data collection.

Patients and methods: 88 Spanish primary care (PC) physicians participated as well as those from Bone Metabolism Unit / Rheumatology and Gynecology units. Patients were females with osteoporosis who started ART in the 12 to 36 months prior to the visit.

Main outcomes: General clinical variables and those related to osteoporosis treatment (both ART and pharmacologic supplements) and an opinion survey on pharmacologic supplements.

Results: 480 patients were included. Mean age (SD) was 65.8 (9.2) years. Pharmacologic supplements were prescribed in 69.6% of patients and were more frequent in patients treated in Bone Metabolism/Rheumatology Units (89.1%) than patients treated by PC (60.3%) and Gynecology (55.6%). In the physician survey, 72% of the Bone Metabolism / Rheumatology Unit physicians responded that the Vitamin D supplements were necessary for treatment of osteoporosis vs. 38.5% of PC physicians (p=0.058).

Conclusions: The use of pharmacologic supplements in the onset of treatment with ART represents more than 60% of the sample, although differences were seen between specialists, with a greater percentage of patients with supplements in the Bone Metabolism/Rheumatology Units than in PC and Gynecology, despite guidelines primarily recommend the use of pharmacologic supplements in these patients.

PubMed Disclaimer

Similar articles

Observational study of treatment compliance in women initiating antiresorptive therapy with or without calcium and vitamin D supplements in Spain.

Díez A, Carbonell C, Calaf J, Caloto MT, Nocea G. Díez A, et al. Menopause. 2012 Jan;19(1):89-95. doi: 10.1097/gme.0b013e318223bd6b. Menopause. 2012. PMID: 21934533

[Analysis of therapeutic compliance in women with osteoporosis].

Carbonell Abella C, Guañabens Gay N, Regadera Anechina L, Marín Rives JA, Taverna Llauradó E, Ayechu Redín MP; ADHEPOR. Carbonell Abella C, et al. Reumatol Clin. 2011 Sep-Oct;7(5):299-304. doi: 10.1016/j.reuma.2010.12.003. Epub 2011 May 4. Reumatol Clin. 2011. PMID: 21925445 Spanish.

Importance of calcium, vitamin D and vitamin K for osteoporosis prevention and treatment.

Lanham-New SA. Lanham-New SA. Proc Nutr Soc. 2008 May;67(2):163-76. doi: 10.1017/S0029665108007003. Proc Nutr Soc. 2008. PMID: 18412990 Review.

Prescriptions for vitamin D among patients taking antiresorptive agents in Canada.

Hanley DA, Zhang Q, Meilleur MC, Mavros P, Sen SS. Hanley DA, et al. Curr Med Res Opin. 2007 Jun;23(6):1473-80. doi: 10.1185/030079907X188198. Epub 2007 May 18. Curr Med Res Opin. 2007. PMID: 17559742

Calcium and vitamin D in the prevention and treatment of osteoporosis - a clinical update.

Boonen S, Vanderschueren D, Haentjens P, Lips P. Boonen S, et al. J Intern Med. 2006 Jun;259(6):539-52. doi: 10.1111/j.1365-2796.2006.01655.x. J Intern Med. 2006. PMID: 16704554 Review.

# data[].attributes.attachment_link.keywords[]
bone density conservation agents / therapeutic use*

# data[].attributes.attachment_link.keywords[]
national center for biotechnology information

# data[].attributes.attachment_link.title
[Initial treatment trends in patient with osteoporosis: use of antiresorptive agents and pharmacologic supplements (calcium and vitamin D) in clinical practice] - PubMed

# data[].attributes.attachment_link.description
The use of pharmacologic supplements in the onset of treatment with ART represents more than 60% of the sample, although differences were seen between specialists, with a greater percentage of patients with supplements in the Bone Metabolism/Rheumatology Units than in PC and Gynecology, despite guid ...

# data[].attributes.headline
Bisfosfonatos para la osteoporosis inducida por corticosteroides

# data[].attributes.subject
Bisfosfonatos para la osteoporosis inducida por corticosteroides

# data[].attributes.body
Allen, C. S., Yeung, J. H., Vandermeer, B., & Homik, J. (2016). Bisphosphonates for steroid-induced osteoporosis. Cochrane Library, 2016(10). https://doi.org/10.1002/14651858.cd001347.pub2

# data[].attributes.headline
Efecto sinérgico de un bifosfonato con Vitamina D

# data[].attributes.subject
Efecto sinérgico de un bifosfonato con Vitamina D

# data[].attributes.body
Velazquez Dominguez, José Antonio, & Morales Espindola, Rubi Ixchell. (2021). Efecto sinérgico de un bifosfonato con vitamina D. Revista Cubana de Investigaciones Biomédicas, 40(1), . Epub 01 de abril de 2021. Recuperado en 23 de junio de 2024, de http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S0864-03002021000100013&lng=es&tlng=es.

# data[].attributes.attachment_link.readable_text
Referencias bibliográficas

1. Vidal MA, Medina C, Torres LM. Seguridad de los bifosfonatos. Rev Soc Esp Dolor. 2011;18(1):43-55. [ Links ]

2. Hinshaw WB, DeLong AF. An Evaluative History of Bisphosphonate Drugs: Dual Physiologic Effects of Pyrophosphate as Inspiration fora Novel Pharmaceutical Class. J Osteoporos. 2016;2016:e1426279. DOI: 10.1155/2016/1426279 [ Links ]

3. Hawkins F, Jódar E, Martínez G. Bases moleculares del mecanismo de acción de los bifosfonatos. REEMO. 2000;9(5):169-71. [ Links ]

4. DeLuca HF. History of the Discovery of vitamin D and its active metabolites. Bonekey Rep. 2014;3(479):1-8. DOI: 10.1038/bonekey.2013.213 [ Links ]

6. Manzano F, Ramos J, Melguizo L, Illescas R, Ruiz C, García O. Bisphosphonate Modulation of the Gene Expression of Different Markers Involved in Osteoblast Physiology: Possible Implications in Bisphosphonate-Related Osteonecrosis of the Jaw. Int J Med Sci. 2018;15(4):359-67. DOI: 10.7150/ijms.22627 [ Links ]

7. Mendes V, Dos Santos GO, Calasans MD, Granjeiro JM, Moraschini V. Impact of bisphosphonate therapy on dental implant outcomes: An overview of systematic review evidence. Int J Oral Maxillofac surg. 2018;48(3):373-81. DOI: 10.1016/j.ijom.2018.09.006 [ Links ]

8. Roddy E, Muller S, Paskins Z, Hider SL, Bucknall MB, Mallen CD. Incident acute pseudogout and prior bisphosphonate use: Matched case-control study in the UK- clinical practice research datalink. Medicine (Baltimore). 2017;96(12):e6177. PMID: 28328803 [ Links ]

9. Ozaras N, Rezvani A. Diffuse skeletal pain after administration of alendronate. Indian J Pharmacol. 2010;42(4):245-6. DOI: 10.4103/0253-7613.68435 [ Links ]

11. Sheikh Z, Chen G, Jaf F A, Thévenin M, Banks K, Glogauer M, et al11. . In Vivo11. bone effects of a novel bisphosphonate -EP4a conjugate drug (C3) for reversing osteoporotic bone loss in an ovariectomized rat model. JBMR Plus. 2019;3(12):e10237. DOI: 10.1002/jbm4.10237 [ Links ]

12. Hauser M, Siegrist M, Keller I, Hofstetter W. Healing of fractures in osteoporotic bones in mice treated with bisphosphonates-A transcriptome analysis. Bone. 2018;(112):107-19. DOI: 10.1016/j.bone.2018.04.017 [ Links ]

13. Shinkai I, Ohta Y. New Drugs-Reports of new drugs recently approved by the FDA. Bioorg Med Chem. 1996;4 (1):3-4. DOI: 10.1016/0968-0896(96)00042-9 [ Links ]

14. Barreira E. Antirresortivos. Ortho-tips. 2010;6(1):63-72. [ Links ]

15. Machairiotis N, Ntali G, Kouroutou P, Michala L. Clinical evidence of the effect of bisphosphonates on pregnacy and the infant. Horm Mol Biol Clin Investig. 2019;40(2). DOI: 10.1515/hmbci-2019-0021 [ Links ]

16. Teixeira S, Branco L, Fernandes MH, Costa RJ. Bipshosphonates and Cancer: A Relationship Beyond the Antiresorptive Effects. Mini Rev Med Chem. 2019;19(12):988-98. DOI: 10.2174/1389557519666190424163044 [ Links ]

18. Cortez-Franco F. Vitamina D y análogos. Dermatol Perú. 2014;24(1):27-33. [ Links ]

19. Žmitek K, Hribar M, Hristov H, Pravst I. Efficiency of vitamin D supplementation in healthy adults in associated with body mass index and baseline serum 25-hidroxyvitamin D Level. Nutrients. 2020;12(5). DOI: 10.3390/nu12051268 [ Links ]

22. Walash MI, Metwally ME, Eid M, EI-Shaheny RN. Validated spectrophotometric methods for determination of Alendronate sodium in tablet through nucleophlic aromatic substitution reactions. Chem Cent J. 2012;6(25):1-15. DOI: 10.1186/1752-153X-6-25 [ Links ]

23. Bikle DD. Vitamin D Metabolism, Mechanism of Action, and Clinical Applications. Chem Biol. 2014;21(3):319-29. DOI: 10.1016/j.chembiol.2013.12.016 [ Links ]

24. Rojas E. Osteoporosis. Rev Med Cos Cen. 2015;(615):477-81. [ Links ]

25. Binkley N, Ringe JD, Reed JI, Ljunggren Ö, Holick MF, Minne HW, et al25. . Alendronate/vitamin D3 70 mg/2800 IU with and without additional 2800 IU vitamin D ₃25. for osteoporosis: Results from the 24 weeks extension of a 15-week randomized, controlled trial. Bone. 2009;44(4):639-47. DOI: 10.1016/j.bone.2008.05.002 [ Links ]

26. Aisa A, Rosas M, Reza M, Díaz E, Rodríguez FL. Tratamiento de la osteoporosis en pacientes de alto riesgo: El manejo del internista. Acta Med. 2013;11(3):137-44. [ Links ]

27. Zuluaga NA, Alfaro JM, Balthazar V, Jiménez KE, Campuzano G. Vitamina D: nuevos paradigmas. Medicina & Laboratorio. 2011;17(5-6): 211-46. [ Links ]

29. Straube S, Derry S, Straube C, Moore RA. Vitamin D for the treatment of chronic painful conditions in adults. Cochrane Database Syst Rev. 2015;(5):CD007771. DOI: 10.1002/14651858.CD007771.pub2 [ Links ]

30. Cantorna MT, Snyder L, Lin YD, Yang L. Vitamin D and 1,25 (OH) ₂30. D Regulation of T cells. Nutrients. 2015;7(4):3011-21. DOI: 10.3390/nu7043011 [ Links ]

31. Miao Z, Wang S, Wang Y, Guo L, Zhang J, Liu Y, Yang Q. A potential linking between vitamin D and adipose metabolic disorders. Can J Gastroenterol Hepatol. 2020;2656321. DOI: 10.1155/2020/2656321 [ Links ]

32. Chuguransky SR, Cortizo AM, McCarthy AD. Alendronate can improve bone alterations in experimental diabetes by preventing antiosteogenic, antichondrogenic, and proadipocytic effects of AGEs son bone marrow progenitor cells. Biomed Res Int. 2016;1-13. DOI: 10.1155/2016/5891925 [ Links ]

34. Mitchell A, Watts AE, Ebetino FH, Suva LJ. Biphosphonate use in the horse: what is good and what is not? BMC Vet Res. 2019;15:211. DOI: 10.1186/s12917-019-1966-x [ Links ]

35. Berkhout J, Stone JA, Verhamme KM, Danhof M, Post TM. Disease systems analysis of bone mineral density and bone turnover markers in response to alendronate, placebo, and washout in postmenopausal women. CPT: Pharmacometrics & Syst. Pharmacol. 2016;5(12):656-64. DOI: 10.1002/psp4.12135 [ Links ]

36. Koiwai H, Kamimura M, Takahashi J, Nakamura Y, Kato H. Unexpected rapid increase in bone mineral density by bisphosphonate therapy after multiple spinal fractures: a case report. J Med Case Rep. 2019;13:288. DOI: 10.1186/s13256-019-2219-0 [ Links ]

37. Simpione G, Caldas RJ, Soares MQS, Rubira-Bullen IRF, Santos PSS. Tomographic study of Jaw bone changes in patients with bisphosphonate-related osteonecrosis. J Clin Exp Dent. 2020;12(3):e285-e290. DOI: 10.4317/jced.56265 [ Links ]

38. Zhang Y, Chen X, Tang Y, Lu Y, Guo L, Zhong D. Bioequivalence of generic alendronate sodium tablets (70 mg) to Fosamax® tablets (70 mg) in fasting, healthy volunteers: a randomized, open-label, three-way, reference-replicated crossover study. Drug Des Devel Ther. 2017;11:2109-19. DOI: 10.2147/DDDT.S138286 [ Links ]

39. Carretero M Alendronato Sódico. Offarm. 2002;21(11):138-40. [ Links ]

41. Molvik H, Khan W. Bisphosphonates and their influence on fracture healing: a systematic review. Osteoporos Int. 2015;26(4):1251-60. DOI: 10.1007/s00198-014-3007-8 [ Links ]

44. Rudnick S, Corem E, Grinberg I, Yehuda R, Margel S. Near IR fluorescent conjugated poly (ethyleneglycol) bisphosphonate nano particles for in vivo bone targeting in a young mouse model. J Nanobiotechnol. 2015;13(80):1-8. DOI: 10.1186/s12951-015-0126-0 [ Links ]

45. Shin YH, Shin WC, Kim JW. Effect of Osteoporosis Medication on Fracture Healing: An Evidence Based Review. J Bone Metab. 2020;27(1):15-26. DOI: 10.11005/jbm.2020.27.1.15 [ Links ]

46. González CA, Barahona RR. Mode of action of vitamin D3, 1-α-hydroxycholecalciferol (1-α-OH-D3) and 25-hydroxycholecalciferol (25-OH-D3) in commercial laying hens. Rev CES Med Vet Zootec. 2014;9(1):114-27. [ Links ]

47. Sang-Min J, Eun-Ae S. Exploring vitamin D metabolism and function in cancer. Exp Mol Med. 2018;50(4):20. DOI: 10.1038/s12276-018-0038-9 [ Links ]

48. Sassi F, Tamone C, D'Amelio P. Vitamin D: Nutrient, Hormone, and Inmmunomodulator. Nutrients. 2018;10(11):1656. DOI: 10.3390/nu10111656 [ Links ]

49. Peter C, Rodan GA. Preclinical safety profile of alendronate. Int J Clin Pract. 1999;101(Suppl):S3-S8. [ Links ]

52. Chiu W Y, Yang W S, Chien J Y, Lee JJ, Tsai KS. The influence of alendronate and tooth extraction on the incidence of osteonecrosis of the jaw among osteoporotic subjects. PLoS One. 2018;13(4):e0196419. DOI: 10.1371/journal.pone.0196419 [ Links ]

53. Yu-Hung Y, Jen-Hung H, Hung-Ewn C, Yung-Kuo L, Chien-Yeh H, Yi-Jen C. Vitamin D and bisphosphonates therapies for osteoporosis are associated with different risks of atrial fibrillation in women. Medicine (Baltimore). 2018;97(43):e12947. DOI: 10.1097/MD.0000000000012947 [ Links ]

54. Gómez LG, González D. Possible ocular adverse effects attributable to bisphosphonate therapy: Two case reports. Rev Colomb de Reumatol. 2017;24(1):54-9. DOI: 10.1016/j.rcreue.2017.04.001 [ Links ]

55. Taylor PN, Davies JS. A review of the growing risk of vitamin D toxicity from inappropriate practice. Br J Clin Pharmacol. 2018;84(6):1121-7. DOI: 10.1111/bcp.13573 [ Links ]

56. Tarantino U, Iolascon G, Cianferotti L, Masi L, Marcucci G, Giusti F. Clinical guidelines for the prevention and treatment of osteoporosis: summary statements and recommendations from the Italian Society for Orthopaedics and Traumatology. J Orthop Traumatol. 2017;18(Suppl 1):S3-S36. DOI: 10.1007/s10195-017-0474-7 [ Links ]

57. Wen-Hung H, Shen-Yang L, Cheng-Hao W, Ping-Chin L. Use of Alendronate Sodium (Fosamax) to Ameliorate Osteoporosis in Renal Transplant Patients: A Case-Control Study. PLoS One. 2012;7(11):1-8. DOI: 10.1371/journal.pone.0048481 [ Links ]

# data[].attributes.attachment_link.title
Efecto sinérgico de un bifosfonato con vitamina D

# data[].attributes.attachment_link.description
Referencias bibliográficas 1. Vidal MA, Medina C, Torres LM. Seguridad de los bifosfonatos. Rev Soc Esp Dolor. 2011;18(1):43-55. [ Links ] 2. Hinshaw WB, DeLong AF. An Evaluative History of Bisphosphonate Drugs: Dual Physiologic Effects of Pyrophosphate as Inspiration fora Novel Pharmaceutical Class. J Osteoporos. 2016;2016:e1426279. DOI: 10.1155/2016/1426279 [ Links ] 3.

# data[].attributes.headline
Uso de bifosfonatos, calcio y vitamina D en el tratamiento de osteoporosis en farmacia privada.

# data[].attributes.subject
Uso de bifosfonatos, calcio y vitamina D en el tratamiento de osteoporosis en farmacia privada.

# data[].attributes.body
De Grado, M. L. F. E. S. (2020). Uso de bifosfonatos, calcio y vitamina D en el tratamiento de osteoporosis en farmacia privada. http://repositorio.udec.cl/jspui/handle/11594/6571

# data[].attributes.attachment_link.readable_text
Por favor, use este identificador para citar o enlazar este ítem: http://repositorio.udec.cl/jspui/handle/11594/6571

Este ítem está sujeto a una licencia Creative Commons Licencia Creative Commons

# data[].attributes.attachment_link.title
Repositorio Bibliotecas UdeC: Uso de bifosfonatos, calcio y vitamina D en el tratamiento de osteoporosis en farmacia privada.

# data[].attributes.attachment_link.description
Por favor, use este identificador para citar o enlazar este ítem: http://repositorio.udec.cl/jspui/handle/11594/6571 Este ítem está sujeto a una licencia Creative Commons Licencia Creative Commons

# data[].attributes.headline
Tratamiento de la osteoporosis. Revisión sistemática

# data[].attributes.subject
Tratamiento de la osteoporosis. Revisión sistemática

# data[].attributes.body
Guevara, J. R. V. (2023). Tratamiento de la osteoporosis. Revisión sistemática. Avances en Biomedicina, 12(1), 1.

# data[].attributes.wish_content.attachment_props.alternative_text
Tratamiento de la osteoporosis. Revisión sistemática

# data[].attributes.headline
Papel del calcio y la vitamina D en el tratamiento de la osteoporosis 

# data[].attributes.subject
Papel del calcio y la vitamina D en el tratamiento de la osteoporosis 

# data[].attributes.body
Recker, RR; Cannata Andía, JB; del Pino Montes, J; Díaz Curiel, M; Nogués i Solán, X; Valdés Llorca, C; Sosa Henríquez, M; Gómez de Tejada Romero, MJ Papel del calcio y la vitamina D en el tratamiento de la osteoporosis Revista de Osteoporosis y Metabolismo Mineral, vol. 2, núm. 1, marzo, 2010, pp. 61-72 Sociedad Española de Investigación Ósea y del Metabolismo Mineral Islas Canarias, España

# data[].attributes.body
Canales Tapia Vanessa

García Miranda Valeria Judith

Sánchez González Abigail